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Thereisnottoomuchsuccessintheantioxidanttreatmentofheartdeceasesinhumans.Howeveranewapproachisnowdeveloped
that suggests that depending on their structures and concentrations antioxidants can exhibit much more complicated functions in
many pathological disorders. It is now well established that physiological free radicals superoxide and nitric oxide together with
their derivatives hydrogen peroxide and peroxynitrite (all are named reactive oxygen species (ROS) and reactive nitrogen species
(RNS)) play a more important role in heart diseases through their signaling functions. Correspondingly this work is dedicated
to the consideration of damaging signaling by ROS and RNS in various heart and vascular disorders: heart failure (congestive
heart failure or CHF), left ventricular hypertrophy (LVH), coronary heart disease, cardiac arrhythmias, and so forth. It will be
demonstrated that ROS overproduction (oxidative stress) is a main origin of the transformation of normal physiological signaling
processes into the damaging ones. Furthermore the favorable eﬀects of low/moderate oxidative stress through preconditioning
mechanisms in ischemia/reperfusion will be considered. And in the last part we will discuss the possibility of eﬃcient application
of antioxidants and enzyme/gene inhibitors for the regulation of damaging ROS signaling in heart disorders.
1.Introduction
Heart disease (cardiopathy) and cardiovascular diseases are
a group of numerous pathological disorders such as heart
failure (congestive heart failure or CHF), left ventricular
hypertrophy (LVH), coronary heart disease, cardiac arrhyth-
mias, and so forth, in which signaling processes of reactive
oxygen and reactive nitrogen species (ROS and RNS) play
an important (probably critical) role. Contemporary studies
identiﬁed major sources of ROS and RNS productions:
NADPH oxidases (Nox), xanthine oxidase, mitochondria,
andnitricoxidesynthases(NOS).Asarule,heartandcardio-
vascular diseases are characterized by ROS overproduction
whereastheformationofmajorRNSsnitricoxide(afreerad-
ical) and peroxynitrite (diamagnetic molecule) can decrease
or increase depending on the nature of heart injury. Free
radicals are usually considered to be the damaging factors in
various pathologies, but on the other hand ROS and RNS
are important signaling species in many physiological and
pathophysiological processes. For example the critical role of
these species has been shown in preconditioning and other
survival processes (see below). A major aim of this work is to
consider the role of ROS and RNS signaling in various heart
and cardiovascular diseases.
2.NADPH OxidasesasROS Producersin
Heart andCardiovascularDiseases
NADPH oxidases generate superoxide by the one-electron
reduction of dioxygen:
2O2 +NADPH −→ 2O2
•− +NADP+ +H + (1)
Family of NADPH oxidases (Nox) consists of several isoen-
zymes. In addition to phagocyte NADPH oxidase (Nox2), six
homologs(Nox1,Nox3,Nox4,Nox5,Duox1,andDuox2)are
now identiﬁed in nonphagocytic cells; however, their role in
cardiovascular and heart diseases might be quite diﬀerent.
ROS generation by NADPH oxidases in heart diseases has
previously been discussed [1–3]. It has been suggested
that the Nox-dependent ROS signaling is an important2 Oxidative Medicine and Cellular Longevity
factor responsible for the development of many pathological
processes in heart.
2.1. Phagocyte NADPH Oxidase Nox2. Phagocyte NADPH
oxidase Nox2 plays important role in heart injury. Bendall et
al. [4] found that Nox2 (gp91phox) was an important factor
of the development of Ang II-induced cardiac hypertrophy
independently of the change in blood pressure in mice.
Similar eﬀect of NADPH oxidase-derived superoxide was
demonstrated by Nakagami et al. [5] Li et al. [6] showed
that ROS generation by phagocyte NADPH oxidase in car-
diomyocytes induced the pressure overload LV hypertrophy.
The elevated expression of NADPH oxidase and superoxide
production was found in the carotid body from rabbits
with chronic heart failure [7]. Similarly Doerries et al.
[8] demonstrated the enhanced activity of NADPH oxidase
subunit p47phox (Nox2) in the mouse left ventricular (LV)
myocardium after myocardial infarction (MI). While Nox2
was required for the response to Ang II-induced left ventric-
ular hypertrophy (LVH), another NADPH oxidase isoform
Nox4 was apparently involved in the cardiac response to
pressure overload in murine myocardium [9].
It was found that Rac1 initiated hypertrophic response
in the heart dependent on NADPH oxidase-generated ROS
[10]. Hingtgen et al. [11] conﬁrmed that superoxide pro-
duction by a Rac1-regulated Nox2 initiated the Ang II-
induced activation of protein kinase Akt in cardiomyocyte
hypertrophy. Judkins et al. [12] showed that Nox2 was
responsible for vascular ROS production, reduced NO
bioavailability, and the early lesion development in aorta of
the mice. Buday et al. [13] found that the elevated circulating
transforming growth factor beta (TGF-β) induced NADPH
oxidase activation and ROS overproduction that accelerated
atherosclerosis, hypertension, and myocardial remodeling in
apolipoprotein E-deﬁcient (apoE(−/−)m i c e .
2.2. NADPH Oxidase Nox4. NADPH oxidase Nox4 is a
NADPH oxidase isoenzyme which plays an important role
in heart and vascular diseases. Martyn et al. [14]s u g g e s t e d
that Nox4 connected to the protein p22phox on internal
membranes in epithelial cells. It was also found that in con-
trast to the other NADPH oxidase isoforms Nox4 produced
mainly hydrogen peroxide and the very small amounts of
superoxide. Cytosolic oxidase proteins or the GTPase Rac are
not required for the activity of this enzyme. Serrander et al.
[15] also found that Nox4 produced hydrogen peroxide but
also generated superoxide intracellularly.
There is a lot of uncertainty in the studies of Nox4-
dependent ROS production. Conclusion that Nox4 produces
mainly hydrogen peroxide and not superoxide contradicts
a majority of the other experimental data. It is possible
thatunreliablemethodssuchasnitrobluetetrazolium(NBT)
reduction were applied for superoxide detection in the above
works[14–16].Ontheotherhandtheuseofthemostspeciﬁc
andprecisemethodoflucigeninchemiluminescence(CL)for
superoxidedetectiongavediﬀerentresults[17].Forexample,
using lucigenin CL, Guzik et al. [18] found that Nox4 and
Nox2 produced about 75% superoxide in coronary arteries
from patients with coronary artery disease (CAD).
Nox4 is apparently located in diﬀerent way in cardiac
cells comparing to other NADPH oxidases. Thus Kuroda
et al. [19] found that Nox4 was localized in mitochondria
and was a major source of superoxide production in cardiac
myocytes. Upregulation of Nox4 increased mitochondrial
superoxide in response to pressure overload (PO). These
authors also showed that Nox4 induced mitochondrial dys-
function, apoptosis in cardiac myocytes, and LV dysfunction
in response to PO. Ago et al. [20] demonstrated that Nox4
was upregulated in aged mice under hypertrophic stimula-
tion, including pressure overload. Overexpression of Nox4
in the heart increased superoxide production and induced
cardiac dysfunction accompanied by enhanced ﬁbrosis and
apoptosis. These authors also conﬁrmed that Nox4 was
localized primarily at mitochondria.
Surprisingly,Zhangetal.[21]foundthatNox4facilitated
cardiac adaptation to chronic stress. In contrast to the other
NADPH oxidase isoforms, Nox4 stimulation in cardiomy-
ocytes led to the protection against pressure overload-
induced adverse cardiac remodeling. Authors explain these
surprising results by the Nox4-induced preservation of myo-
cardial capillary density during pressure overload through
the activation of hypoxia inducible factor 1 (Hif1) and the
release of vascular endothelial growth factor (VEGF). They
also found that the Nox4 location in cardiomyocytes was in
perinuclear endoplasmic reticulum.
Obviously these ﬁndings contradict those obtained by
Kuroda et al. [19]. In both works Nox4-deleted mice were
used but both groups of authors obtained contradictory data
concerning the eﬀects of Nox4 on oxidative stress in cardiac
myocytes and Nox4 localization. Origin of that diﬀerence
is unknown but it should be stressed that the data in
[21] contradict a majority of ﬁndings concerning NADPH
oxidase eﬀects in cardiomyocytes and other cells.
2.3. NADPH Oxidase Nox1. Zhang et al. [22] suggested that
Nox1 was a major NADPH oxidase isoform responsible
for extracellular superoxide production in coronary arterial
myocytes (CAMs).
3. ROS Productionby XanthineOxidasein
Heart andCardiovascularDiseases
Principal reaction catalyzed by xanthine oxidase (XO) is the
oxidation of xanthine into uric acid:
XO + H2O+O 2 −→ uric acid+H2O2 (2)
This catalytic process is accompanied by production of
superoxide:
XO + O2 −→ XO
−1 +O 2
•− (3)
In contrast to the role of NADPH oxidase in heart diseases
which was now ascertained with good certainty, the partici-
pation of xanthine oxidase in ROS-dependent cardiac injuryOxidative Medicine and Cellular Longevity 3
caused earlier many doubts. Xanthine oxidase (XO) and
xanthinedehydrogenase(XDH)aretheoxidizedandreduced
formsofxanthineoxidoreductase(XOR).XOwasconsidered
tobeamajorproducerofsuperoxideandhydrogenperoxide;
its mechanism has been now well established [16,p a g e s
701–703]. Paradoxically, McCord et al. [23]a n dC h a m b e r s
et al. [24] suggested that xanthine oxidase was a main ROS
producer in heart as early as in 1985 just about 5 years
after epochal discovery of superoxide generation by xanthine
oxidase [25]. Although this suggestion has been initially
widelyaccepted,subsequentstudiesdiscoveredaverylowXO
activity in animal and human hearts [26, 27].
However, it is now generally agreed that there is a signif-
icant increase in cellular XO level and activity in the cardio-
vascular system under pathological conditions even though
these changes may not be easily detected under physiological
conditions. For example Thompson-Gorman and Zweier
measured xanthine oxidase-mediated free radical generation
in isolated rat heart [28]. They found that xanthine oxidase
was an important factor of oxidative damage occurred
upon the reperfusion of ischemic rat heart. It has been
also shown that the burst of XO-catalyzed ROS production
upon reperfusion was triggered by the enhancement of
substrate concentration (xanthine and hypoxanthine) due
to the degradation of ATP during ischemia [29]. Ashraf
and Samra also suggested that XO activity increased during
ischemia and intensiﬁed after reperfusion [30]. They found
that XO was localized in interstitial cells, coronary vessel
endothelium, and smooth muscle cells. De Jong et al. [31]
showed that ROS production by xanthine oxidoreductase
(XOR) increased in failing heart but not in hypertrophic
heart.
Similarly to NADPH oxidases xanthine oxidase stim-
ulated many ROS-dependent heart disorders. Landmesser
et al. [32] showed that the increased XO activity and dimin-
ished extracellular superoxide dismutase (ecSOD) activ-
ity impaired endothelium-mediated vasodilation (FDD) in
patients with chronic heart failure (CHF). In subsequent
work Landmesser et al. [33] determined the XO protein
levels and XO-dependent superoxide production in Ang II-
induced endothelial cells from patients with coronary dis-
ease. They suggested that Ang II promoted superoxide over-
production by redox-sensitive XO activation.
Duncan et al. [34] found that xanthine oxidase activity
was elevated in a mouse model of dilated cardiomyopa-
thy. Chronic inhibition of xanthine oxidase by allopurinol
suppressed the progression of heart failure in dilated car-
diomyopathy. Baldus et al. [35] found that ROS produced
by xanthine oxidase impaired coronary NO bioavailability
in patients with coronary artery disease (CAD). Minhas
et al. [36] showed that the spontaneously hypertensive/heart
failure (SHHF) rats exhibited the enhanced mRNA expres-
sion and activity of xanthine oxidoreductase (XOR), but
XOR inhibition caused reverse remodeling in SHHF rats
with dilated cardiomyopathy. Zhang et al. [37] demonstrated
that myocardial ischemia/reperfusion (I/R) enhanced the
expression of tumor necrosis factor (TNF-α) and induced
the activation of xanthine oxidase and superoxide generation
leading to coronary endothelial dysfunction in a murine
model. Yamamoto et al. [38] showed that xanthine oxidore-
ductase and NADPH oxidase enhanced cardiac superoxide
formation in Dahl salt-sensitive hypertensive rats with dias-
tolic heart failure. Gonzalez et al. [39] demonstrated another
toxic eﬀect of superoxide generated by XO in spontaneously
hypertensive heart failure rats with dilated cardiomyopathy.
It was found that superoxide impaired S-nitrosylation of the
ryanodine receptor (RyR) is responsible for calcium leak in
sarcoplasmic reticulum (SR) of skeletal muscle.
4.ROS Productionby Mitochondriain
Heart andCardiovascularDiseases
Mitochondria are an essential ROS producer in heart
and vascular diseases although its signiﬁcance as a ROS
source comparing to NADPH oxidases and xanthine oxidase
remains a subject for discussion. It is now well established
that superoxide is generated by mitochondria due to electron
leak from the two electron carriers of respiratory chain;
these sources of superoxide are Complex I and Complex III
[40]. Many authors conﬁrmed importance of mitochondria-
dependent ROS overproduction in heart damage. Thus Ide
et al. [41] showed that mitochondrial Complex I was a
potentialROSsourceinthefailingmyocardiuminthecanine
hearts. Chen et al. [42] found that ischemia enhanced ROS
production from the isolated rat heart mitochondria. Carpi
et al. [43] demonstrated the crucial role of mitochondrial
ROS formation in ischemia/reperfusion injury by the abla-
tion of p66(Shc) protein in the mouse hearts. Chen et
al. [44] showed that an increase in superoxide production
(supposedly by mitochondria) was responsible for coronary
endothelial dysfunction and decreased coronary blood ﬂow
(CBF) in congestive heart failure (CHF) in dogs.
Redout et al. [45] have studied ROS generation in the
progression of ventricular hypertrophy to congestive heart
failure. They found that both NADPH oxidase and mito-
chondria were the sources of ventricular ROS production in
a rat model of right-ventricular (RV) heart failure induced
by pulmonary arterial hypertension (PAH). Surprisingly, the
enhanced activity of mitochondrial Complex II (and not
Complexes I and III, major mitochondrial ROS producers)
was particularly important for ventricular ROS production
in heart failure. In contrast Mariappan et al. [46] showed
that TNF-α-induced mitochondrial superoxide production
impaired respiratory complex I activity and led to mitochon-
drial damage in the left ventricle (LV) in rats. Mitochondrial
depolarization and enhanced ROS production mediated by
lipoxygenase and arachidonic acid were probablyresponsible
for arrhythmias following ischemia-reperfusion injury [47].
However, mitochondrial superoxide production in damaged
heart might also induce the damage of mitochondrial
electron transfer chain. Thus Chen et al. [48] found that
superoxide suppressed the electron transfer activity of Com-
plex II in postischemic myocardium in the rats subjected to
coronary ligation followed by reperfusion. The aforemen-
tioned ﬁndings suggest that ROS overproduction by mito-
chondria might be an additional origin of heart disorders.4 Oxidative Medicine and Cellular Longevity
5. ROS and RNS Production by
NitricOxide SynthasesinHeart and
CardiovascularDiseases
Nitric oxide synthases (NOS) catalyze conversion of L-
arginine to L-citrulline and nitric oxide but under uncou-
pling conditions these enzymes also produce superoxide:
NOS+L-arginine +O2 +NADPH
−→ NO+ci trulli n e+N ADP +
NOS(Fe(II)heme)+O 2
−→ NOS(Fe(III)heme)+O 2
•−
(4)
Two NOS isoforms neuronal NOS (nNOS, NOS1) and
endothelial NOS (eNOS, NOS3) are constitutively expressed
in cardiomyocytes while inducible NOS (iNOS, NOS2)
is absent in the healthy heart but its expression might
be stimulated by prooxidants [49]. Thus Lijun et al. [50]
showed that hypertrophied myocytes exhibited the elevated
level of iNOS. However, Chen et al. [51]foundtheexpression
of all genes regulated NO synthases was reduced in the hearts
of patients with coronary heart disease (CHD).
As NOSs are able to produce both RNS and ROS, the
eﬀectsoftheseenzymesoncardiovascularsystemcanbevery
complicated—they can enhance or diminish heart damage.
Nitric oxide is the endothelium-derived relaxing factor
(EDRF); therefore its function must be mainly favorable
at the heart. However, the diﬀusion-controlled reaction of
nitric oxide with superoxide produces the highly reactive
peroxynitrite, a really harmful agent.
Khadour et al. [52] have studied the formation of nitric
oxide, superoxide, and peroxynitrite in the hearts from lipo-
polysaccharide- (LPS-) treated rats. They found an increase
in the levels of all these reactive species in dysfunctional
hearts from endotoxemic rats. Takimoto et al. [53] showed
that pressure overload triggered the uncoupling of endothe-
lial nitric oxide synthase NOS3 and enhanced mitochondrial
superoxideproductionthatinduceddilatoryremodelingand
cardiac dysfunction in mice. Liu et al. [54] showed that the
loss of inducible nitric oxide synthase (iNOS) in knock-
out mice (iNOS−/−) attenuated cardiac remodeling and
dysfunction and improved cardiac reserve postmyocardial
infarction (MI) probably due to a decrease in peroxynitrite
formation.
6. Interactionbetween ROS/RNS
ProducedEnzymes
Regulation of superoxide/nitric oxide balance is important
for the prevention of heart damage. This balance is partly
achieved by the interaction of principal enzymatic ROS pro-
ducers during pathological changes in heart. Thus Saavedra
et al. [55] showed that NO synthases and xanthine oxidase
participated in the regulation of myocardial mechanical
eﬃciency and that the upregulation of XO relative to NOS
contributed to mechanoenergetic uncoupling in dogs with
pacing-induced heart failure. Khan et al. [56] demonstrated
that NOS1, as opposed to NOS3, directly interacted with
xanthine oxidase in sarcoplasmic reticulum of cardiac
myocytes in mice regulating cardiac excitation-contraction
coupling. Therefore NOS1 is not only responsible for the
regulation of calcium cycle in sarcoplasmic reticulum but
also exhibits antioxidant activity through XO inhibition.
Saraiva et al. [57] suggested that the disruption of leptin
(anadipose derivedhormone)intheheartmaycontributeto
obesity-related cardiac disease such as cardiac hypertrophy
and enhanced cardiac apoptosis. They showed that leptin
deﬁciency in mice was linked to decreased cardiac expression
ofNOS1andNOproduction,withaconcomitantincreasein
XOR activity and oxidative stress. Thus leptin is apparently
able to change the NOS1/XO balance. Suematsu et al. [58]
found that low sodium diet can induce the activation of
rennin-angiotensin system, enhance superoxide generation
by NADPH oxidase, and diminish NO bioavailability in the
hearts of mongrel dogs. They suggested that low sodium
might be responsible for increased mortality in patients.
7.ROS SignalinginPreconditioning
A brief episode of myocardial ischemia makes the heart
remarkably resistant to a subsequent ischemia, the phe-
nomenon named ischemic preconditioning. It has now been
shown that ROS and RNS signaling play an important
role in ischemic preconditioning and cardioprotection. For
example it was found that 30min of ischemia triggered by
acetylcholine and an opioid receptor in isolated rabbit hearts
stimulated preconditioning which included the activation of
ROS- and RNS-dependent cascade of the epidermal growth
factor (EGF) receptor, phosphatidylinositol 3-kinase (PI3-
K), protein kinase B (Akt), nitric oxide synthase (NOS), and
ROS-dependent opening of mitochondrial (mito)K(ATP)
channels [59]. This cascade might also include extracellular
signal-regulatedkinase(ERK)locatedbetweenAktandnitric
oxide synthase.
Kimura et al. [60] found that both mitochondria and
NADPHoxidasemediatedthepreconditioningeﬀectsofAng
II in rat cardiac I/R injury in vivo through the enhanced
cardiac mitochondria-derived ROS-initiated enzymatic cas-
cade of NADPH oxidase/c-Jun amino-terminal kinase JNK
and p38 MAPK protein kinases. Duda et al. [61] proposed
that in guinea pig hearts ischemic preconditioning (IPC)
raised endothelial protection by preventing postischemic
endothelin-induced superoxide generation and the open-
ing of mitochondrial ATP-dependent potassium channel
(mK(ATP)). Superoxide was produced by NADPH oxidase
and xanthine oxidase. Yue et al. [62] found that precon-
ditioning in rat hearts can be stimulated by menadione-
dependentsuperoxideproduction.Ischemicpreconditioning
reduced myocardial infarction by a mechanism that involved
opening of mitochondrial ATP-dependent potassium chan-
nels (mK(ATP)), ROS formation, and possibly the activation
of p38 mitogen-activated protein kinase (p38 MAPK).
It is usually proposed that both K(ATP) channel opening
and ischemic preconditioning protect the ischemic heart
by acting at K(ATP) channels in the inner mitochondrial
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the isolated rat heart partial mitochondrial uncoupling
induced by low-dose of the protonophore and uncoupler of
mitochondrial oxidative phosphorylation FCCP signiﬁcantly
improved ROS-dependent postischemic functional recovery.
This cardioprotection was not mediated by the depletion of
cellular ATP or mitochondrial K(ATP) channel activation.
Van-Cuong et al. [64] studied dynamic changes in nitric
oxide produced by iNOS and eNOS and mitochondrial
superoxide production during anoxic preconditioning (AP)
in rat hearts. Under these conditions NO production played
a pivotal role in scavenging of high levels of superoxide
during post-anoxia/reoxygenation. These authors suggested
that the continuous superoxide increase in preconditioning
stimulated cell survival by the protection of cells from
a sudden ROS shock at the onset of reoxygenation. Major
signaling pathway in anoxic preconditioning was probably
NO/cyclic guanosine monophosphate cGMP-protein kinase
G (PKG)/ATP-sensitive potassium channel (KATP). Koneru
et al. [65] demonstrated importance of the glucose trans-
porter type 4 (GLUT-4) translocation and association in IP
rat myocardium mediated by ROS signaling in Akt/eNOS/
caveolin 3(Cav-3) enzymatic cascade. Juhaszova et al. [66]
suggested that the mitochondrial permeability transition
pore (mPTP) was a key end eﬀector of ischemic/pharmaco-
logical pre- and postconditioning. Enhancement of ROS
formation might induce mPTP-dependent resistance of car-
diomyocytes to oxidant stress and infarct size reduction.
Cohen et al. [67] have reviewed the mechanisms of enzy-
matic signaling pathways in ischemic preconditioning inﬂu-
enced by nitric oxide. They showed that the phosphorylation
of nitric oxide synthase induced nitric oxide production, the
subsequent activation of guanylyl cyclase, the production of
cyclic guanosine monophosphate, the activation of protein
kinase G, and opening of mitochondrial KATP channels.
These processes were followed by ROS generation, which
activated the critical kinase cascades of phospholipase Cδ,
PI3K, and ERK kinases. It is thought that these processes
stimulate the inhibition of mitochondrial permeability tran-
sition pore formation and trigger the entrance into the pre-
conditionedstate.InrecentworkVigneronetal.[68]showed
that in the isolated-perfused mouse hearts preconditioning
stimulated the downregulation of glycogen synthase kinase-
3β (GSK-3β), the opening of mitoK(ATP), and ROS gener-
ation activating the target of rapamycin (mTOR) pathway
and induced cardioprotection. These ﬁndings suggest that
cardioprotection involved a prosurvival mTOR pathway.
8. Mechanismsof ROS andRNS Signalingin
HeartandCardiovascularDiseases
Overproduction of ROS and deregulation of RNS produc-
tion are important factors of the development of heart
and cardiovascular diseases. Mechanisms of ROS and RNS
generation by major producers, NADPH oxidases, xanthine
oxidase, mitochondria, and nitric oxide synthases in these
diseases as well as in preconditioning were discussed above
and presented in Table 1(a). Now we will discuss the
mechanisms of ROS and RNS signaling in heart pathological
states.
8.1. ROS and RNS Signaling in the Processes Catalyzed by
Protein Kinases B and C. Among various enzymes, protein
kinases B and C and mitogen-activated protein kinases
(MAPK) play a very important role in ROS and RNS-
dependent enzymatic cascades responsible for heart damage.
One of these kinases is the serine/threonine protein kinase
B (Akt). It has already been noted that Akt participates in
Nox2-initiated Ang II-dependent cardiomyocyte hypertro-
phy [11]. Recently Hingtgen et al. [86] demonstrated that an
increase in cytoplasmic superoxide levels and Akt activation
were responsible for the pressure overload-induced activa-
tionofnuclearfactorNF-κBandcardiomyocytehypertrophy
in mice. As it has been already noted, Akt also participates
in preconditioning [59, 65]. There are examples of diﬀerent
signaling eﬀects of Akt kinase. Chen et al. [69] found that
NADPH oxidase-induced ROS activated Akt and ERK1/2
MAPK in cascade aﬀected angiogenic growth factor expres-
sion and angiogenesis in mouse myocardium undergoing
ischemia/reperfusion (I/R). Feng et al. [70] proposed that
ROS levels aﬀected NO-mediated coronary vasodilatation
in mouse heart endothelial cells through NADPH oxidase-
induced ROS/PI3-K/Akt/eNOS cascade. Akt signaling is also
an important factor of gene-mediated processes (see below).
Participation of protein kinases PKC, PKCδ,a n dP K C ε
in heart damaging processes has been also demonstrated
[67, 71, 87]. Monti et al. [71] suggested that the activation
of PKC kinases in coronary endothelial cells might inﬂu-
ence the imbalance of eNOS/ROS system and endothelial
dysfunction. It was found that selective inhibition of PKCδ
or selective activation of PKCε reduced oxidative damage in
the heart following myocardial infarction. cGMP-dependent
protein kinase (PKG) showed protective activity in the heart
[88, 89].
8.2. ROS and RNS Signaling in Processes Catalyzed by Mito-
gen-Activated Protein Kinases MAPKS. Widder et al. [72]
found that the activation of vascular p38 MAP kinase and
its downstream target kinase MAPKAPK-2 in rats with heart
failure was related to the elevated formation of superoxide
and the reduction of NO bioavailability. They proposed
that the activation of vascular p38 kinase in the heart
failure caused the induction and activation of NADPH
oxidase and superoxide overproduction. Gaitanaki et al.
[73] showed that hyperthermia stimulated ROS-dependent
activation of p38 and JNKs MAP kinases in the isolated
perfused amphibian heart. Heusch et al. [74] demonstrated
ROS formation, myoﬁbrillar protein oxidation, and p38
kinase activation in failing rabbit heart. They found that
p38 activation took place upstream rather than downstream
of ROS formation which stimulated LV function through
myoﬁbrillar oxidation. Satoh et al. [75] showed that long-
term treatment with17β-Estradiol (E2) improved congestive
heart failure (CHF) in rats by antioxidative mechanism
that involved thioredoxin (Trx) upregulation, the inhibi-
tion of Rac1(small GTPase-) mediated NADPH oxidase
activity, and the apoptosis signal-regulating kinase 1(ASK-
1)/JNK/p38-mediated apoptosis. Cai et al. [76] studied the
eﬀe c to fc r o c e t i no nc a r d i a ch y p e r t r o p h y .I tw a sf o u n dt h a t
crocetin inhibited ROS-dependent MAPK [kinase kinase]6 Oxidative Medicine and Cellular Longevity
Table 1
(a) ROS Generation by NADPH oxidases in heart and cardiovascular diseases. Nox2 activation and ROS production in the stimulation of
pressure overload LV hypertrophy and Ang II-induced cardiac hypertrophy [5, 6, 8, 11]. Induction of atherosclerosis, hypertension, and
myocardial remodeling by transforming growth factor-beta- (TGF-β-) stimulated NADPH oxidase-dependent ROS production [13].
Stimulation of mitochondrial dysfunction, apoptosis, LV dysfunction, cardiac dysfunction, and cardiac adaptation to chronic stress by
Nox4-dependent superoxide generation [19–21]. Nox1-dependent extracellular superoxide in coronary arterial myocytes [22].
Nox2 −→ ROS −→ pressure overload LV hypertrophy Li et al. [6]
Nox2 −→ ROS −→ Ang II-induced cardiac hypertrophy Nakagami et al. [5]
Nox2 −→ activation in LV myocardium after MI Doerries et al. [8]
Rac1-regulated Nox2 −→ Ang II-Akt activation −→ cardiomyocyte hypertrophy Hingtgen et al. [11]
TGF-β −→ NADPH oxidase −→ ROS −→ atherosclerosis↑, hypertension↑− → myocardial remodeling Buday et al. [13]
Nox4 −→ ROS −→ mitochondrial dysfunction, apoptosis, LV dysfunction in response to pressure
overload Kuroda et al. [19]
Nox4 overexpression −→ O2
•− −→ cardiac dysfunction −→ ﬁbrosis, apoptosis Ago et al. [20]
Nox4 −→ O2
•− −→ cardiac adaptation to chronic stress Zhang et al. [21]
Nox1 −→ extracellular O
•−
2 ↑ in coronary arterial myocytes Zhang et al. [22]
(b) Xanthine oxidase as ROS producer in heart and cardiovascular diseases. Suppression of extracellular (ecSOD) and impaired
endothelium-mediated vasodilation (FDD) in heart failure by Ang II-XO-produced superoxide [32, 33]. XO activation in dilated
cardiomyopathy [34]. Impaired coronary NO bioavailability in patients with coronary artery disease (CAD) [35]. Expression of tumor
necrosis factor (TNF-α), XO activation, and superoxide generation in myocardial I/R and coronary endothelial dysfunction [37].
Superoxide production by xanthine oxidoreductase and NADPH oxidase in hypertensive rats with diastolic heart failure [38]. Impairment
of S-nitrosylation of the ryanodine receptor in spontaneously hypertensive heart failure rats by XO-generated superoxide [39].
AngII −→ XO −→ O2
•− −→ ecSOD↓− → impaired FDD in heart failure Landmesser et al. [32, 33]
Dilated cardiomyopathy −→ XO activity↑ Duncan et al. [34]
XO −→ ROS −→ NO↓ in patients with CAD Baldus et al. [35]
I/R −→ TNF-α −→ XO activation −→ O2
•− −→ coronary endothelial dysfunction Zhang et al. [37]
XO + NADPH oxidase −→ O2
•− −→ diastolic heart failure Yamamoto et al. [38]
XO −→ O2
•− −→ S-nitrosolation↓− → cardiomyopathy, hypertensive heart Gonzalez et al. [39]
(c) Mitochondrial ROS production in heart and cardiovascular diseases. Complex I as ROS producer in the failing myocardium [41].
Enhancement of coronary endothelial dysfunction and decrease in coronary blood ﬂow (CBF) in congestive heart failure (CHF) in dogs
by mitochondrial superoxide [44]. Ventricular ROS production by NADPH oxidase and mitochondria in a rat model of the
right-ventricular (RV) heart failure with pulmonary arterial hypertension (PAH) [45]. TNF-α-induced impairment of Complex I in the
left ventricle (LV) in rats by mitochondrial superoxide [46]. Suppression of Complex II in postischemic myocardium in the rats with
coronary ligation by superoxide [48].
Complex I −→ ROS −→ failing myocardium Ide et al. [41]
Mitochondria (?)−→ O2
•− −→ coronary endothelial dysfunction↓ in CHF in dogs Chen et al. [44]
Complex II + NADPH oxidase −→ ROS −→ PAH −→ RV heart failure Redout et al. [45]
TNF-α −→ mitochondrial O2
•− −→ Complex I activity↓, LV damage Mariappan et al. [46]
O2
•− −→ Complex II activity↓ in postischemic myocardium Chen et al. [48]
(d) ROS and RNS signaling in preconditioning. Activation of the epidermal growth factor (EGF) receptor, phosphatidylinositol 3-kinase
(PI3-K), Akt, ERK (?), NOS, and ROS-dependent (mito)K(ATP) channels by acetylcholine and an opioid receptor [59]. Preconditioning
eﬀects of Ang II at cardiac I/R injury via mitochondrial ROS-initiated cascade of NADPH oxidase-JNK and p38 protein kinases [60].
Menadione-dependent superoxide initiation of ischemic preconditioning and reduction of myocardial infarction by potassium channels
(mK(ATP)) and p38 MAPK [62]. Anoxic preconditioning through NO-cGMP-PKG-KATP cascade [64]. Activation of glucose transporter
type 4 GLUT-4 translocation mediated by ROS-induced Akt/eNOS/Cav-3 enzymatic cascade [65]. Mechanism of ischemic
preconditioning through NOS, guanylyl cyclase, PKG, and KATP channels with subsequent ROS generation and activation of
phospholipase C, PKC, PI3-K, and ERK kinases [67].
Acetylcholine or opioid receptor −→ EGF receptor↑,P I 3 - K↑,A k t ↑, ERK?, NOS↑− → ROS-dependent
opening of (mito)K(ATP)channels PRECONDITIONING Philipp et al. [59]Oxidative Medicine and Cellular Longevity 7
Table 1: Continued.
AngII −→ ROS −→ NADPH oxidase −→ JNK −→ p38 −→ PRECONDITIONING Kimura et al. [60]
Menadione −→ O2
•− −→ mK(ATP) opening −→ p38 −→ PRECONDITIONING Yue et al. [62]
NO −→ c-GMP −→ PKG −→ KATP −→ ANOXIC PRECONDITIONING Van-Cuong et al. [64]
GLUT-4 −→ ROS −→ Akt −→ eNOS −→ caveolin-3 −→ ISCHEMIC PRECONDITIONING Koneru et al. [65]
p-NOS −→ NO −→ guanylyl cyclase −→ cGMP −→ PKG −→ KATP −→ ROS −→ phospholipase C
−→ PKC −→ PI3-K −→ ERK −→ ISCHEMIC PRECONDITIONING
(e) ROS signaling in damaging enzymatic cascades in the heart. Expression of angiogenic growth factor and angiogenesis in I/R
myocardium stimulated by NADPH oxidase-induced ROS [69]. Endothelium-dependent vascular endothelial growth factor regulation of
coronary vascular tone by ROS/NADPH oxidase/PI3-K/Akt/eNOS cascade [70]. Reduction of oxidative damage in the heart with
myocardial infarction by inhibition of PKCδ or activation of PKCε [71]. Activation of NADPH oxidase and superoxide overproduction
through p38 kinase and MAPKAPK-2 kinase in the heart failure [72]. Stimulation of ROS-dependent activation of p38 and JNKs kinases
in the isolated perfused amphibian heart by hyperthermia [73]. ROS formation, myoﬁbrillar protein oxidation, and p38 kinase activation
in failing rabbit heart [74]. Improvement of congestive heart failure (CHF) through thioredoxin (Trx) upregulation, inhibition of NADPH
oxidase and ASK-1/JNK/p38-mediated apoptosis by 17β-Estradiol (E2) treatment [75]. Inhibition by crocetin of ROS-dependent
MAPK/(MEK/ERK1/2) pathway and stimulation of hypertrophy in cardiac myocytes and ﬁbroblasts [76]. Activation of JNK and p38
kinases and the induction of p53 and PUMA (p53 upregulated modulator of apoptosis) stimulated by MCP-1-induced protein (MCPIP)
[77]. Protection of cardiomyocytes by IKK-NF-κB signaling cascade due to a decrease in oxidative stress and JNK activation [78].
Recombinant TNF- (rTNF-) induced superoxide production in cardiomyocytes and cardioﬁbroblasts, concomitant with expression of
matrix metalloproteinases MMPs [79]. ROS-induced expression of phosphodiesterase type 5 (PDE5) in cardiac myocytes and the
d e v e l o p m e n to fc o n g e s t i v eh e a r tf a i l u r e( C H F )[ 80]. ROS production by NADPH oxidase and the activation of CaMKII (calmodulin
kinase II) after depolarizations (EADs) and cardiac arrhythmias [81].
NADPH oxidase −→ ROS −→ Akt −→ ERK1/2 −→ angiogenesis in I/R myocardium Chen et al. [69]
NADPH oxidase −→ ROS −→ PI3-K −→ Akt −→ eNOS −→ VEGF regulation of coronary vascular
tone Feng et al. [70]
PKCδ inhibition
Oxidative damage↓− →Myocardial infarction↓
−→
− →
PKCε activation
Monti et al. [71]
Heart failure −→ P38↑− → MAPKAPK-2 −→ NADPH oxidase −→ O2
•−↑ +N O ↓ Widder et al. [72]
Hyperthermia −→ ROS↑− → p38↑ and JNKs ↑ in heart Gaitanaki et al. [73]
P38 −→ ROS −→ LV stimulation in failing rabbit heart Heusch et al. [74]
E2 −→ Trx↑− → NADPH oxidase↓− → ASK-1/c-Jun/p38↓− → apoptosis↓− → CHF recovery Satoh et al. [75]
Crocetin −→ ROS/MEK/ERK1/2 ↓− → cardiac hypertrophy↓ Cai et al. [76]
MCP-1 −→ ROS −→ MCPIP −→ (JNK + p38)↑ p53
−
→
−→
−
→
Apoptosis Autophagy
Heart failure
Younce and Kolattukudy [77]
IKK-NF-κB −→ ROS↓− → JNK↓− → pressure overload↓ Hikoso et al. [78]
rTNF −→ PI3K −→ O2
•−↑− →MMP↑ Awad et al. [79]
ROS −→ PDE5↑− → CHF stimulation Lu et al. [80]
EAD, arrhythmias −→ Ang II −→ NADPH oxidase −→ ROS −→ CaMKII ↑ Zhao et al. [81]
(f) ROS signaling in gene/enzymatic processes in heart. Suppression of age-dependent cardiac hypertrophy, apoptosis, cardiac
dysfunction, and expression of senescence markers by Sirt1 upregulation in response to low/moderate oxidative stress. In contrast
enhancement by a high level of Sirt1 of these damaging disorders [82]. Sirt3 suppression of cardiac hypertrophic response through
Foxo-dependent MnSOD and catalase and the suppression of ERK and PI3K/Akt activation [83]. p66Shc participation in an
α1-adrenergtic receptor (α1-AR) pathway together with PKCε and PKCδ and the induction of Akt-FOXO3a phosphorylation in
cardiomyocytes [84]. FoxO1 and FoxO3 nuclear localization and target gene activation by oxidative stress in cardiomyocytes [85].
ROS (low levels) −→ Sirt1↑
Decrease in hypertrophy, apoptosis, cardiac dysfunction, cell senescence
ROS (high levels) −→ Sirt1↑↑
−
→
−
→
Increase in hypertrophy, apoptosis, cardiac dysfunction, cell senescence
Alcendor et al. [82]8 Oxidative Medicine and Cellular Longevity
Table 1: Continued.
Sirt3 −→ MnSOD↑, catalase↑− → ROS↓− → PI3K/Akt/ERK↓− → Cardiac hypertrophy↓ Sundaresan et al. [83]
P66Shc −→ PKCε and PKCδ −→ Akt-FOXO3a phosphorylation −→ hypertrophy↓ Guo et al. [84]
AMPK −→ FOX1 + FOX3 −→ MnSOD↑ + catalase↑− → survival Sengupta et al. [85]
(MEK)/ERK1/2 pathway responsible for hypertrophy in
primary cultured cardiac myocytes and ﬁbroblasts and in
a one animal model of cardiac hypertrophy. Zhang et al.
[90] showed that tumor necrosis factor TNF-α inhibited
endothelium-dependent NO-mediated dilation of coronary
arterioles from porcine heart by the ceramide-induced
activation of JNK and subsequent production of superoxide
by xanthine oxidase.
Younce and Kolattukudy [77] studied the role of MCP-
1 (monocyte chemotactic protein-1) in the development of
heart failure and apoptosis. They showed that MCP-1 caused
death of cardiac myoblasts by inducing ROS formation and
endoplasmic reticulum (ER) stress leading to autophagy
via a novel zinc-ﬁnger protein, MCPIP (MCP-1-induced
protein). MCPIP stimulated enzymatic cascade through the
activation of MAP kinases JNK and p38. These ﬁndings
suggested that MCPIP induced ROS/RNS production that
stimulated ER stress, autophagy and apoptosis. Hikoso et al.
[78] investigated the protective role of nuclear factor NF-
κB in cardiomyocytes in response to pressure overload. They
demonstrated that IκB kinase (IKK)-(NF-κB) signaling cas-
cade was protective in cardiomyocytes due to the attenuation
of oxidative stress and JNK activation.
8.3. Other ROS-Dependent Enzymatic and Gene/Enzymatic
Signaling Pathways in Heart Disorders. It has been shown
that tumor necrosis factor (TNF-α) is upregulated in a num-
ber of cardiomyopathies inducing adverse cardiac remod-
eling and dilation due to the degradation of the extracel-
lular matrix by matrix metalloproteinases (MMPs). Awad
et al. [79] found that recombinant TNF-α (rTNF) induced
stronger superoxide production and increased expression of
several MMPs in mouse neonatal cardiomyocytes comparing
to cardioﬁbroblasts. Phosphatidylinositol 3-kinase (PI3K-γ)
mediated TNF-dependent superoxide production and MMP
expression. Lu et al. [80] have studied the expression of
phosphodiesterase type 5 (PDE5) in left ventricular samples
from patients with end-stage congestive heart failure (CHF)
and normal donors and from mice after transverse aortic
constriction-induced CHF. It was found that ROS increased
PDE5 expression in cardiac myocytes and stimulated the
CHF development in patients and in the mice.
Shan et al. [91] have studied myocardial ischemia/re-
perfusion (I/R) injury in diabetic hearts. They showed
that the inhibition of Rac1signaling prevented NADPH
oxidase activation and ROS overproduction resulting in the
inhibition of calpain (calcium-activated neutral protease)
activation. It was concluded that Rac1 activation increased
I/R injury in diabetic hearts and was mediated by calpain
activation. Zhao et al. [81] suggested that Ang II induced
intracellular ROS production by NADPH oxidase and the
activation of CaMKII (calmodulin kinase II) after depo-
larizations (EADs) and cardiac arrhythmias. Mechanisms
of ROS signaling in harmful enzymatic heart processes are
presented in Table 1.
It is known that several genes (p66Shc, sirtuin family,
Klotho, and Foxo3a) regulate ROS formation in pathological
states. Thus it has been shown that the suppression of p66shc
gene stimulates stress resistance and prolongs lifespan in
experimental animals. FOXO3a belonging to the O subclass
of the forkhead family of transcription factors is considered
to be a regulator of longevity and cancer. The eﬀects of silent
information regulator Sirtuin (human Sirt1 and Sirt3 and
yeast Sir2) proteins depend on ROS levels and can stimulate
or decrease longevity of experimental animals. Klotho gene
regulates cell senescence and aging. Mechanisms of ROS
regulation in such gene/enzymatic processes were recently
discussed [92].
These genes can also participate in ROS-dependent heart
damage. Alcendor et al. [82] showed that Sirt1 was upreg-
ulated in response to low/moderate oxidative stress in adult
mouse hearts causing the suppression age-dependent cardiac
hypertrophy, apoptosis, and cardiac dysfunction. In contrast
the high levels of Sirt1 enhanced these heart disorders.
Sundaresan et al. [83] found that Sirt3 can block cardiac
hypertrophic response in mice through the activation of
Foxo-dependent antioxidative enzymesMnSODandcatalase
and the suppression of ROS-mediated ERK and PI3K/Akt-
dependent signaling pathways.
Guo et al. [84] showed that the p66Shc adapter protein
participated in an α1-adrenergtic receptor (α1-AR) pathway
together with protein kinases PKCε and PKCδ and induced
Akt-FOXO3a phosphorylation in rat cardiomyocytes. Sen-
gupta et al. [85] showed that the regulation of transcription
factors FoxO1 and FoxO3 by AMP-activated protein kinase
(AMPK) and the activation of MnSOD and catalase were
necessary for promotion of cardiomyocyte survival under
conditions of oxidative stress (Table 1). The aforementioned
ﬁndings demonstrate that the eﬀects of genes in heart disor-
ders might diﬀer from those in the other pathological states.
p66Shc is a negative regulator of cardiomyocyte hypertrophy
and a major regulator of ROS production and cardiovascular
oxidative stress responses. Thus p66Shc eﬀects in heart
diseases disagree with its eﬀect on ROS stimulation in aging
[92].
9. AntioxidantsandFree RadicalScavengersas
Suppressors of ROS-Induced Heart Disorders
For a long time antioxidants were considered important
pharmacological agents for the treatment of heart diseases. It
is impossible to discuss even a small part of works published
on this problem (at present MEDLINE cites more 12400Oxidative Medicine and Cellular Longevity 9
works on Heart Diseases and Antioxidants), therefore we
need to choose some principal studies. Antioxidants and
free radical scavengers can suppress free radical-dependent
heart disorders by direct reactions with reactive hydroxyl
and peroxy free radicals or through the regulation of ROS
signaling in gene- and enzyme-catalytic cascades. We will
consider some important examples.
It has been shown that classical scavengers such as the
grape-derived polyphenol resveratrol and synthetic phenol
Probucolshowedmultifacetedcardioprotectiveactivities[93,
94]. Another antioxidant recommended for the treatment of
heart patients is L-arginine. Tripathi et al. [95] showed that
oraladministrationofL-argininetopatientswithanginaand
myocardial infarction might be protective due to an increase
in plasma superoxide dismutase and total thiols. It should be
noted that L-arginine is the substrate of NO synthases and
thereforetheenhancementofNOproductioncanbeanother
source of its protective action.
SuperoxideisaoneoftwomajorsignalingROS,therefore
the regulation of SOD activity can be important for the
suppression of heart disorders. For example van Deel et al.
[96] showed that the deﬁciency of EC-SOD (extracellular
superoxide dismutase) gene enhanced oxidative stress in the
leftventricular(LV),hypertrophy,andﬁbrosisinmice.These
ﬁndings suggest that EC-SOD plays an important role in
the heart protection against oxidative stress and infarction-
induced ventricular hypertrophy. Gaitanaki et al. [97]f o u n d
that ascorbic acid, SOD, or catalase inhibited ROS-induced
activation of p38 MAPK in amphibian hearts. Ding et al.
[98] showed that the transfer of adenoviral CuZnSOD (Ad
CuZnSOD) gene to the carotid body increased CuZnSOD
protein expression and reduced the baseline renal sympa-
thetic nerve activity (RSNA) and the response of RSNA
to hypoxia in rabbits with chronic heart failure. Recently
Piantadosi et al. [99] showed that endogenous carbon
monoxide (CO) generated by heme oxygenase-1 (HO-1)
exhibited antioxidant eﬀect by the stimulation of SOD-2
upregulation and mitochondrial production of hydrogen
peroxide. It was suggested that the initiation of the HO-
1/CO signaling through transcription factor Nrf2 and Akt
kinase B stimulated the myocardial transcriptional program
for mitochondrial biogenesis. Chen et al. [100] showed that
omega-3 fatty acids prevented cardiac ﬁbrosis and cardiac
dysfunction by the activation of cyclic GMP/protein kinase
G pathway in mouse cardiac ﬁbroblasts.
Recent ﬁndings conﬁrmed the protective eﬀect of silde-
naﬁl (Viagra) against ischemia-reperfusion injury in the
heart. It has been proposed that Sildenaﬁl, a selective
inhibitor of phosphodiesterase type 5 induced powerful pro-
tection against myocardial I/R injury through the activation
of cGMP-dependent protein kinase G (PKG). Das et al.
[101] suggested that the PKG-activated survival kinase ERK
stimulated sildenaﬁl-induced cardioprotection through the
induction of eNOS/iNOS synthases. It was concluded that
PKG-dependent ERK phosphorylation was the origin of
eNOS/iNOS induction and cardioprotection by sildenaﬁl.
Thus antioxidants of various classes might be considered
tobeofpotentialuseforthepreventionandmaybetreatment
of heart and cardiovascular diseases.
10. Discussion
The data discussed in this work show that practically all
pathological disorders in heart and cardiovascular system are
associated with damaging ROS signaling. These damaging
processes can be initiated by ROS overproduced by various
sources such as NADPH oxidases, mitochondria, xanthine
oxidase,andNOsynthases(Table 1),ornormalphysiological
signaling processes might be converted into damaging ones
by ROS-induced transformation of catalytic cascades. There
are various factors which can be responsible for damaging
ROS overproduction: aging, obesity, ischemia/reperfusion,
hypertension, high-fat diet, low-molecular prooxidants,
metal ions, and so forth [102–105].
It is seen from Table 1 that ROS activate various enzyme/
gene cascades in heart disorders. Protein kinases A-G and
MAP kinases ERK, P38, and JNK apparently play an impor-
tant role in these processes. However, the same enzymes are
members of ROS-dependent normal physiological processes,
therefore their transformation in pathological ones might be
a consequence of ROS overproduction [40]. Indeed in many
heart disorders (ischemia/reperfusion, changes of coronary
vascular tone, myocardial infarction, LV dysfunction, cardiac
hypertrophy, EAD, arrhythmias, or heart failure) prooxidant
enzymes and proteins such as NADPH oxidases, Ang II,
TNF-α, or monocyte chemotactic protein-1 (MCP-1) are
responsible for ROS overproduction. ROS overproduction
might be also initiated by cellular disorders for example
initiated by hyperthermia (Table 1).
On the other hand ROS signaling in enzymatic/gene
cascades might also decrease disorders in heart and cardio-
vascular system. As is seen from Table 1,P K C δ inhibition
or PKCε activation caused the suppression of oxidative
stress and the reduction of myocardial infarction [71]. 17β-
estradiol (E2) increased the expression of thioredoxin (Trx)
and the suppression of NADPH oxidase/ASK-1/c-Jun/p38
cascade causing a decrease in apoptosis and the stimulation
of CHF recovery [75]. Decrease in ROS signaling led to the
reduction of cardiac hypertrophy and pressure overload in
cardiomyocytes [76, 78].
It is of interest that the participation of certain genes
in signaling pathways frequently led to diminishing heart
d i s o r d e r s .A si ss e e nf r o mTable 1,l o wR O Sl e v e l sr e s u l t e d
in a decrease in hypertrophy, apoptosis, cardiac dysfunction,
and cell senescence through moderate upregulation of Sirt1
while severe oxidative stress strongly upregulated Sirt1 and
enhanced heart dysfunctions [82]. On the whole p66Shc and
FOXO genes regulated ROS-dependent cascades diminishing
hypertrophy and enhancing cell survival [84, 85]. ROS and
RNS signaling under the conditions of moderate oxidative
stressalsoleadstothesuppressionofheartdisordersthrough
preconditioning.
As ROS overproduction is one of the most important
stimulators of heart disorders, it is logically to suggest that
the application of antioxidants should be useful for ﬁghting
the heart and cardiovascular diseases. It has been shown
above that the eﬀects of antioxidants are very complicated
and changed from direct interactions of antioxidants with10 Oxidative Medicine and Cellular Longevity
reactive free radicals to the inﬂuence of enzymatic/gene
pathways. For example protein kinases and the antioxi-
dant/prooxidant genes can enhance or diminish ROS forma-
tion stimulating surviving and death of cardiomyocytes.
Another source of diﬃculty is dependence of the eﬀects
of antioxidants or prooxidants and various ROS inhibitors
dependent on the levels of oxidative stress. As it was pointed
out, low levels of ROS (low oxidative stress) might have
prosurvival eﬀects while high ROS levels (severe oxidative
stress)willdamagebiomolecules.Theseeﬀectscaninturnbe
complicated by the survival eﬀects of prooxidants-induced
preconditioning and the induction of antioxidant enzymes
(MnSOD and CuZnSOD).
Therefore a major question is how we might take into
account all miscellaneous eﬀects of antioxidants, prooxi-
dants, and gene/enzymatic inhibitors for the selection of the
right compounds and methods in the antioxidant (or proox-
idant) treatment of heart diseases? Of course there is no
simple answer. However, it is probably useful before begin-
ning the treatment of patients to consider possible eﬀects
of the selected compound in major ROS and RNS signaling
processes.
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